click below
click below
Normal Size Small Size show me how
CNS Drugs Mechanisms
BS2014 Neuroscience Drug Targets in CNS and proposed mechanisms
Drug Category | Function |
---|---|
Tricyclic Antidepressant - e.g. doxepine | Inhibits re-uptake of NA or 5-HT |
SSRIs (Antidepressants) - e.g. Prozac | Selective serotonin re-uptake inhibitor |
Irreversible MAOIs (Antidepressants) - e.g. phenelzine | Inhibit metabolism of NA by monoamine oxidase inhibition (MAOI) |
α-2 adrenoceptor antagonists (antidepressants) - e.g. mirtrazapine | Enhance release of NA into synaptic cleft by inhibiting negative-feedback inhibition of NA release as triggered by binding of NA to pre-synatptic α-2 adrenoceptors (autoreceptors) |
Manic symptoms (bipolar disorder); Lithium compounds - e.g. Lithium citrate | Interfer with inositol recycling by inhibiting inositol monophosphate. Impacts a major (Gαq) pathway. |
Stimulant; Amphetamine | Sympathomimetic- competes for Uptake 1 and inhibits MOA; prevents NA removal from synaptic cleft. |
Stimmulant; Cocaine | Sympathomimetic - competes with NA for Uptake 1 |
Anti-epileptics (AED)- e.g. phenytoin | Selectively block most active Na+ channels to inhibit the depolarisation. |
Schizophrenia Antipsychotics - e.g. Haloperidol | D2 (dopamine receptor) antagonist (atypical) |
Schizophrenia Antipsychotic - e.g. Clozapine | 5-HT 2A/2C (serotonin)receptor antagonist (atypical) |
Schizophrenia Antipsychotic - e.g. mGluR 2/3 agonist (clinical trials) | Inhibits glutamate release into synaptic cleft |
Opioid Analgesics - e.g. morphine | Opioid GPCR agonist = primarily μ, Gαi; βγ subunit activity on Na+ (deactivation- decreased influx), K+ (activation/ increased efflux) and Ca2+ (downregulated - decreased vesicular exocytosis conductance) - decreased neural excitability |